2008   Print Screen
News Releases
   2010
   2009
   2008
- -2007
-- 2006
-- 2005

DOYLESTOWN, PA, September 9, 2008 – QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, broadcasts that QuantRx’s FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma’s founder and Chief Scientific Advisor, will report on two preclinical studies demonstrating the potential of novel Positron Emission Tomography (PET) molecular imaging agents for

DOYLESTOWN, PA, July 23, 2008 - QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that QuantRx’s FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging.

.

.


                                                                

.

.

 

If you are a stockholder and wish to be added to our electronic mailing list, please email us your name and current email address to receive updates and the latest press releases.

  • DOYLESTOWN, PA, March 20, 2008 -   QuantRx Biomedical Corporation, (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, is commencing Phase I clinical trials for BFPET following institutional review board
  • QuantRx® Biomedical Announces MOU Agreement with Jant Pharmacal
    DOYLESTOWN, PA, March 5, 2008 - QuantRx® Biomedical Corporation (OTC BB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has entered into a Memorandum of Understanding agreement with Jant Pharmacal  to form a strategic alliance to develop and commercialize new technologies and products in the areas of diagnostics and monitoring.        

© Copyright 2007 - QuantRx® Biomedical Corporation